Protagenic Price Sales Ratio from 2010 to 2025

PTIXW Stock  USD 0  0.00  0.00%   
Protagenic Therapeutics Price Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price Sales Ratio will likely drop to 0.000025 in 2025. During the period from 2010 to 2025, Protagenic Therapeutics Price Sales Ratio regression line of quarterly data had mean square error of  0 and geometric mean of  0.0001. View All Fundamentals
 
Price Sales Ratio  
First Reported
2010-12-31
Previous Quarter
0.000026
Current Value
0.000025
Quarterly Volatility
0.06965795
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 24.1 K, Interest Expense of 137.6 K or Selling General Administrative of 1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.42. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Protagenic Therapeutics' Price Sales Ratio Growth Pattern

Below is the plot of the Price Sales Ratio of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Price Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Sales Ratio10 Years Trend
Slightly volatile
   Price Sales Ratio   
       Timeline  

Protagenic Price Sales Ratio Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.0001
Coefficient Of Variation214.84
Mean Deviation0.05
Median0.000023
Standard Deviation0.07
Sample Variance0
Range0.1728
R-Value(0.68)
Mean Square Error0
R-Squared0.46
Significance0
Slope(0.01)
Total Sum of Squares0.07

Protagenic Price Sales Ratio History

2025 2.5E-5
2024 2.6E-5
2013 2.3E-5

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Price Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.